An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.
The discovery, which has the potential to improve melanoma survival rates, was published today in Clinical Cancer Research, a journal of the American Association for Cancer Research.
The research found that patients with high levels of circulating tumour DNA (ctDNA) – an important indicator of cancer in the blood – could potentially benefit from receiving a more aggressive treatment as a first line of defence against melanoma.
